Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients

Kalmarzi, Rasoul Nasiri; Fattahi, Nima; Kaviani, Zeinab; Ataee, Pedram; Mansouri, Majid; Moradi, Ghobad; Yousefzade, A; Abbassi, Javid Morad

doi:10.1016/j.alit.2016.08.008

Cited by 13 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Physiologically, sPD-L1 correlates with immunosuppression as particularly high levels can be observed during pregnancy due to immune suppression securing the maternal acceptance of the placenta. 30 31 Moreover, altered sPD-L1 was detected in immune-modulating diseases such as type I diabetes mellitus, 32 allergic rhinitis 33 and severe sepsis. 34 35 According to the high levels of sPD-L1 observed in patients with glioma in the present cohort, systemic immune suppression might be more pronounced in patients with glioma as compared with other brain tumours and controls.…”

Section: Discussionmentioning

confidence: 99%

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

et al. 2020

View full text Add to dashboard Cite

BackgroundImmune-modulatory treatments have so far shown limited clinical activity in primary brain tumours. We aimed to investigate soluble programmed death receptor ligand 1 (sPD-L1) as systemic inflammation parameter in patients with brain tumour.MethodsEDTA plasma was collected from 81 glioma (55 glioblastoma (GBM), 26 lower-grade glioma (LGG)), 17 meningioma and 44 brain metastasis (BM) patients and 24 controls. sPD-L1 concentrations were determined by ELISA. Correlations with the local tumour microenvironment were assessed by immunohistochemical analysis for PD-L1, CD3 and CD8.ResultssPD-L1 was detected in 62 out of 166 (37.7%) patients (glioma: 41/81, 50.6%; meningioma: 5/17, 29.4%; BM: 7/44, 15.9%; controls: 9/24, 37.5%; p=0.002). sPD-L1 concentrations were lower in BM than in LGG (p=0.003) or GBM (p<0.001). Membranous PD-L1 expression on tumour cells was not associated with sPD-L1 concentrations (p=0.953). sPD-L1 concentration was inversely correlated with the density of CD8+ (r=−0.713, p=0.001) and CD3+ (r=−0.484, p=0.042) tumour-infiltrating lymphocytes in LGG. sPD-L1 is correlated with neutrophil counts (r=−0.318, p=0.045) and C reactive protein levels (r=−0.363, p=0.008) in GBM. sPD-L1+ patients had longer overall survival in GBM (p=0.006) and worse OS in LGG (p=0.028).ConclusionssPD-L1 is detectable in a fraction of patients with brain tumour. Although it is not correlated with tissue PD-L1 expression, correlations with other local and systemic inflammation parameters could be detected in LGG and GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In other allergic diseases, induction of PD‐L1 in B cells of patients with cedar pollinosis suppresses the production of IL‐5 and IL‐13 in CD4‐positive T cells 18 . In patients with allergic rhinitis, there is a negative correlation between the amount of soluble PD‐L1 and the peripheral blood eosinophil count and the severity of allergic rhinitis 19 . Although the mechanism of severe bronchial asthma during ICI use has not been elucidated, it might be speculated that the exacerbation of bronchial asthma, in this case, was mediated by enhancement of Th2‐type inflammation by the anti‐PD‐L1 antibody.…”

Section: Discussionmentioning

confidence: 99%

Successful management of severe bronchial asthma exacerbated by anti‐PD‐L1 treatment: A report of two cases

Sumi

Nagahisa

Matsuura

et al. 2021

Respirology Case Reports

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have been used for various carcinomas. However, immune-related adverse events have been observed. There have been few reports of treatment with biologics for severe bronchial asthma induced by ICI; therefore, their efficacy is unknown. We report two cases of severe bronchial asthma requiring systemic steroid administration while using anti-programmed death-ligand 1 (PD-L1) antibody for advanced non-small-cell lung cancer. The anti-interleukin-5 antibody, mepolizumab, was introduced, resulting in the discontinuation of systemic prednisolone and good asthma control. These reports suggest that treatment with biologics may be effective in severe cases of poorly controlled bronchial asthma during ICI therapy.

show abstract

“…An increasing number of studies have illustrated that the immune checkpoint pathways, such as programmed death receptor 1/ programmed death‐ligand 1 (PD‐1/PD‐L1) may be a key regulating mechanism of human allergic diseases. A significant negative correlation was found between PD‐L1 levels and clinical severity in the patients with allergic rhinitis . In addition, both PD‐L1 and IL‐10 levels were raised upon sublingual immunotherapy in the patients with peach allergy .…”

Section: Introductionmentioning

confidence: 90%

The blockade of PD‐1/PD‐L1 pathway promotes the apoptosis of CD19⁺CD25⁺ Bregs and suppresses the secretion of IL‐10 in patients with allergic rhinitis

Wang

Tan

2019

Scand J Immunol

View full text Add to dashboard Cite

PD‐1/PD‐L1 pathway is crucial to immune regulation by controlling the balance between T cell tolerance and activation. However, the association between PD‐1/PD‐L1 pathway and regulatory B cells has not been fully investigated in allergic rhinitis. In this study, we detected the number of peripheral CD19+CD25+ Bregs and the expression of IL‐10 on this cell subset in healthy control and patients with allergic rhinitis using flow cytometry. Then, we evaluated the level of PD‐L1 in CD19+CD25+ Bregs and investigated the correlation between PD‐L1 and CD4+ follicular T helper cells. Finally, we studied the effects of anti–PD‐L1 on the apoptosis of Bregs and the production of IL‐10. Comparing with healthy controls, the percentage of CD19+CD25+ Bregs and the expression of IL‐10 were both significantly decreased in AR group. In addition, the expression of PD‐L1 on CD19+CD25+ Bregs was also lower in allergic rhinitis patients. Interestingly, a negative correlation was found between the expression of PD‐L1+ Bregs and CD4+CXCR5+ follicular T helper cells. In vitro assay revealed that anti–PD‐L1 promoted Bregs apoptosis and inhibited the expression of IL‐10 in CD19+CD25+ Bregs. Collectively, these results suggest that PD‐L1 expressed on CD19+CD25+ Bregs may be a potential regulator in the treatment of allergic rhinitis. Blockade of PD‐1/PD‐L1 pathway might be a valuable pathogenic target for allergic rhinitis through inhibiting the secretion of immunosuppressive cytokine and promoting CD19+CD25+ Bregs apoptosis.

show abstract

Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients

Cited by 13 publications

References 29 publications

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

Successful management of severe bronchial asthma exacerbated by anti‐PD‐L1 treatment: A report of two cases

The blockade of PD‐1/PD‐L1 pathway promotes the apoptosis of CD19⁺CD25⁺ Bregs and suppresses the secretion of IL‐10 in patients with allergic rhinitis

Contact Info

Product

Resources

About

Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients

Cited by 13 publications

References 29 publications

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

Successful management of severe bronchial asthma exacerbated by anti‐PD‐L1 treatment: A report of two cases

The blockade of PD‐1/PD‐L1 pathway promotes the apoptosis of CD19+CD25+ Bregs and suppresses the secretion of IL‐10 in patients with allergic rhinitis

Contact Info

Product

Resources

About

The blockade of PD‐1/PD‐L1 pathway promotes the apoptosis of CD19⁺CD25⁺ Bregs and suppresses the secretion of IL‐10 in patients with allergic rhinitis